Leif Hendrik Droge
Overview
Explore the profile of Leif Hendrik Droge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Treatment of non-small cell lung cancer: advances following the introduction of PET-CT and IMRT/VMAT
Muster J, Alt N, Edelmann M, Anczykowski M, Zwerenz C, Schirmer M, et al.
Strahlenther Onkol
. 2025 Mar;
PMID: 40050448
Purpose: In definitive radiotherapy/radiochemotherapy (RT/RCT) for localized non-small cell lung cancer (NSCLC), the introduction of positron-emission tomography (PET)-CT-based staging/RT planning and dynamic RT techniques (intensity-modulated radiotherapy, IMRT/volumetric modulated arc therapy,...
2.
Hampe L, Kuffer S, Niemeier T, Scheele N, Hampe L, Riedl A, et al.
Front Immunol
. 2025 Jan;
15:1509051.
PMID: 39763660
Background: Esophageal cancer has a poor prognosis despite treatment advancements. Although the benefit of neoadjuvant chemoradiotherapy (CRT) followed by adjuvant immunotherapy is evident, the effects of CRT on PD-L1 expression...
3.
Leu M, Bohnenberger H, Guhlich M, Schirmer M, Pilavakis Y, Wolff H, et al.
Cancer Rep (Hoboken)
. 2024 Aug;
7(8):e2111.
PMID: 39191673
Background And Aim: The German NPC-GPOH trials introduced treatment including neoadjuvant chemotherapy, radiochemotherapy (RCT) and antiviral treatment in patients aged 25 years or younger with nasopharyngeal cancer (NPC). We conducted...
4.
Ziegler D, Cleve C, Ziegler S, Schirmer M, Fischer L, Bohnenberger H, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893074
In this study, we investigated the outcomes and factors influencing treatment efficacy in 93 patients with limited disease small cell lung cancer (LD-SCLC), with a median age of 64 years....
5.
Edelmann M, Rieken S, Droge L
Strahlenther Onkol
. 2024 Apr;
200(7):649-651.
PMID: 38647565
No abstract available.
6.
Alt N, Muster J, Ziegler D, Bendrich S, Donath S, Hille A, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254817
Identification of the optimal treatment strategy is challenging in elderly with localized non-small cell lung cancer (NSCLC). Concurrent chemotherapy with low-dose cisplatin represents an option for elderly. Outcomes (1) in...
7.
Habermann F, Schmitt D, Failing T, Ziegler D, Fischer J, Fischer L, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201658
The internal organ at risk volume (IRV) concept might improve toxicity profiles in stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC). We studied (1) clinical aspects in...
8.
Guhlich M, Maag T, Droge L, Hille A, Donath S, Bendrich S, et al.
Radiat Oncol
. 2023 Dec;
18(1):203.
PMID: 38124078
Background: Significant bleeding of tumor sites is a dreaded complication in oncological diseases and often results in clinical emergencies. Besides basic local and interventional procedures, an urgent radiotherapeutic approach can...
9.
Guhlich M, Maag T, Droge L, El Shafie R, Hille A, Donath S, et al.
Strahlenther Onkol
. 2022 May;
198(12):1072-1081.
PMID: 35552767
Purpose: Superior vena cava syndrome (SVCS) often results from external vessel compression due to tumor growth. Urgent symptom-guided radiotherapy (RT) remains a major treatment approach in histologically proven, rapidly progressive...
10.
Habermann F, Schmitt D, Failing T, Fischer J, Ziegler D, Fischer L, et al.
Curr Oncol
. 2022 Feb;
29(2):1080-1092.
PMID: 35200591
The pandemic raised a discussion about the postponement of medical interventions for non-small cell lung cancer (NSCLC). We analyzed the characteristics of pretreatment diagnostic assessment in the pandemic and the...